Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.46 |
| ▸ | ACACA | Q13085 | 7/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21025835 | 0.90 | ACACB (0.44) | ACACBACACAHPGDLMNAPLA2G4B | |
| SCHEMBL20372470 | 0.89 | ACACB (0.46) | ACACBACACAHPGDLMNAPLA2G4B | |
| SCHEMBL24788112 | 0.88 | ACACB (0.46) | ACACBACACAHPGDLMNAPLA2G4B | |
| SCHEMBL20325827 | 0.87 | ACACB (0.44) | ACACBACACAHPGDLMNA | |
| SCHEMBL18592240 | 0.86 | HPGD (0.43) | ACACBACACAHPGDLMNA | |
| SCHEMBL21664495 | 0.82 | PLA2G4B (0.44) | ACACBLMNAPLA2G4B | |
| SCHEMBL20234740 | 0.81 | PLA2G4B (0.46) | PLA2G4B | |
| SCHEMBL20331331 | 0.81 | PLA2G4B (0.46) | PLA2G4B | |
| SCHEMBL24762096 | 0.80 | APP (0.48) | PLA2G4B | |
| SCHEMBL21982825 | 0.79 | PLA2G4B (0.49) | PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11028088-B2 | Modulators of BTK proteolysis and methods of use | YALE UNIVERSITY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-01-14 | — | — | US | disclosed |
| US-20190276459-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | YALE UNIVERSITY | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | ACACB 1444/4885ACACA 1820/4885HPGD 3040/4885 |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | ACACB 1444/4885ACACA 1820/4885HPGD 3040/4885 |
| US-11028088-B2 | Modulators of BTK proteolysis and methods of use | BTK, CBL, CRBN | ACACB 1780/4885ACACA 2749/4885HPGD 4471/4885 |
| US-20190276459-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | ACACB 1780/4885ACACA 2749/4885HPGD 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.